Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation

Luigi Di Biase, David Callans, Karl Georg Haeusler, Gerhard Hindricks, Hussein Al-Khalidi, Lluis Mont, Jens Cosedis Nielsen, Jonathan P. Piccini, Ulrich Schotten, Paulus Kirchhof*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)132-138
Number of pages7
JournalEP Europace
Volume19
Issue number1
DOIs
Publication statusPublished - Jan 2017

Keywords

  • Atrial fibrillation
  • Ablation
  • Oral anticoagulation
  • Apixaban
  • Warfarin
  • Un-interrupted
  • Stroke
  • Bleeding
  • ACADEMIC RESEARCH CONSORTIUM
  • PERIPROCEDURAL ANTICOAGULATION
  • RADIOFREQUENCY ABLATION
  • BLEEDING COMPLICATIONS
  • UNINTERRUPTED RIVAROXABAN
  • MEDICARE BENEFICIARIES
  • ORAL ANTICOAGULANTS
  • SAFETY
  • DABIGATRAN
  • MANAGEMENT

Cite this